Unlearn.AI

What Unlearn.AI does

Unlearn.AI transforms clinical development by making every trial smarter. They integrate evidence, modeling, and reasoning to help trial teams make confident decisions. Powered by digital twins, data, and AI, Unlearn aims to accelerate clinical development, reduce trial size, cost, and time to readout, especially in areas like neuroscience, immunology, and metabolic disease. Their platform acts as a scientific intelligence layer for clinical development, supporting planning, monitoring, and analysis.

Products

• Trial Planning and SimulationsA unified AI-enabled workspace for upstream trial design, allowing teams to investigate and compare trial design scenarios, anchor assumptions to credible evidence, and enter governance discussions with clear, defensible rationale. It integrates literature review, historical data exploration, and explainable trial simulations.
• Anomaly Detection & Clinical Data SurveillanceContinuous patient and site-level monitoring of clinical data to detect anomalies as they emerge, such as unexpected values, off-trajectory responders, and multi-variate signals benchmarked against historical patient trajectories.
• Trial Analyses with Digital TwinsStrengthens trial analyses with AI-generated forecasts of clinical trial participants’ expected control outcomes. These digital twins can be used as external comparators in early-stage and open-label studies to reduce variability and improve the ability to detect treatment effects, or in randomized trials to support smaller sample sizes or increased power.

Key capabilities

• Digital twins of patients
• AI-powered decision making
• Integrated evidence, modeling, and reasoning
• Unified workspace for trial design
• AI-powered literature and precedent review (Scout)
• Historical data exploration
• Explainable trial simulations
• Continuous patient and site-level monitoring
• Anomaly detection
• Multi-variate signal benchmarking
• External comparators for early-stage and open-label studies
• Support for smaller sample sizes or increased power in randomized trials

Use cases

• Streamlining clinical trials
• Accelerating clinical development
• Reducing control arm size in trials
• Saving enrollment time in trials
• Optimizing trial design (endpoint, time point, eligibility strategies)
• Validating clinical and statistical assumptions
• Assessing population characteristics, endpoint behavior, and benchmarks
• Evaluating endpoints, inclusion/exclusion criteria, sample size, and constraints
• Detecting anomalies in clinical data
• Strengthening trial analyses
• Enabling clearer go/no-go decisions earlier in development
• More efficient late-stage trials

AI approach

Unlearn.AI uses AI and digital twins to streamline clinical trials. Their platform integrates evidence, modeling, and reasoning to help trial teams make confident decisions. They use AI for literature and regulatory precedent review, historical data exploration, and explainable trial simulations. Their core offering involves AI-generated forecasts of clinical trial participants’ expected control outcomes, referred to as digital twins, which can reduce variability and improve the detection of treatment effects, leading to smaller sample sizes or increased power in trials.

Tech named: Artificial Intelligence, Machine Learning, Digital Twins, Deep Learning, Biostatistics, Computational Biology, Data Science

Industries served

• Biotechnology
• Pharmaceuticals
• Research Services

What it says sets it apart

• Built for trial planning and scientific oversight, beyond document-first protocol platforms
• Integrates evidence review, assumption testing, and scenario comparison before designs are finalized
• Makes assumptions, inputs, and outputs visible across clinical, biostatistics, and regulatory teams earlier, beyond siloed statistical simulation
• Links evidence, historical data, and simulations into a transparent, review-ready workflow, beyond point AI tools
• Focuses upstream on early design decisions, beyond downstream execution systems
• Methodology qualified by the EMA and aligned with current FDA guidance
• Unmatched scientific credibility

Funding rounds we track

From the AI funding tracker — rounds as reported by the linked publications.